

# Richard L Momparler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6791389/richard-l-momparler-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101  
papers

4,342  
citations

37  
h-index

63  
g-index

103  
ext. papers

4,580  
ext. citations

3.9  
avg, IF

5.59  
L-index

#	Paper	IF	Citations
101	Enhancement of the Antileukemic Action of the Inhibitors of DNA and Histone Methylation: 5-Aza-2Fdeoxycytidine and 3-Deazaneplanocin-A by Vitamin C.. <i>Epigenomes</i> , <b>2021</b> , 5,	2.3	1
100	Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy.. <i>Epigenomes</i> , <b>2020</b> , 4,	2.3	2
99	Inhibition of DNA and Histone Methylation by 5-Aza-2Fdeoxycytidine (Decitabine) and 3-Deazaneplanocin-A on Antineoplastic Action and Gene Expression in Myeloid Leukemic Cells. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 19	5.3	17
98	Targeting of cancer stem cells by inhibitors of DNA and histone methylation. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1031-43	5.9	31
97	Phase I and II studies of the decitabine+genistein drug combination in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13556-e13556	2.2	2
96	Epigenetic therapy of acute myeloid leukemia using 5-aza-2Fdeoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. <i>Clinical Epigenetics</i> , <b>2014</b> , 6, 19	7.7	53
95	Pharmacodynamic Responses to DNA Methyltransferase Inhibition <b>2014</b> , 171-188		
94	Pharmacokinetic and pharmacodynamic analysis of 5-aza-2Fdeoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. <i>Clinical Epigenetics</i> , <b>2013</b> , 5, 3	7.7	143
93	Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. <i>Experimental Hematology and Oncology</i> , <b>2013</b> , 2, 20	7.8	32
92	Epigenetic action of decitabine (5-aza-2Fdeoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). <i>Leukemia Research</i> , <b>2013</b> , 37, 980-4	2.7	19
91	Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2Fdeoxycytidine). <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 188	5.3	23
90	Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. <i>Leukemia Research</i> , <b>2012</b> , 36, 1049-54	2.7	33
89	A Perspective on the Comparative Antileukemic Activity of 5-Aza-2Fdeoxycytidine (Decitabine) and 5-Azacytidine (Vidaza). <i>Pharmaceuticals</i> , <b>2012</b> , 5, 875-81	5.2	8
88	3-Deazauridine enhances the antileukemic action of 5-aza-2Fdeoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase. <i>Leukemia Research</i> , <b>2011</b> , 35, 110-8	2.7	16
87	Abstract 4344: Membrane-type 1 matrix metalloproteinase-mediated pro-invasive properties of neuroblastoma initiating cells <b>2011</b> ,		4
86	Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2Fdeoxycytidine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 411-6	3.5	46
85	Importance of dose-schedule of 5-aza-2Fdeoxycytidine for epigenetic therapy of cancer. <i>BMC Cancer</i> , <b>2008</b> , 8, 128	4.8	51

84	Antileukemic activity of genistein, a major isoflavone present in soy products. <i>Journal of Natural Products</i> , <b>2008</b> , 71, 3-7	4.9	44
83	Synergistic effect of 5-Aza-2-Deoxycytidine and genistein in combination against leukemia. <i>Oncology Research</i> , <b>2008</b> , 17, 223-30	4.8	20
82	Preclinical evaluation of the antineoplastic action of 5-aza-2-Deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. <i>Cancer Cell International</i> , <b>2008</b> , 8, 16	6.4	37
81	Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2-Deoxycytidine (decitabine) on human breast carcinoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2006</b> , 58, 618-25	3.5	40
80	Epigenetic therapy of cancer with 5-aza-2-Deoxycytidine (decitabine). <i>Seminars in Oncology</i> , <b>2005</b> , 32, 443-51	5.5	129
79	Pharmacology of 5-Aza-2-Deoxycytidine (decitabine). <i>Seminars in Hematology</i> , <b>2005</b> , 42, S9-16	4	155
78	Preclinical and Clinical Studies on 5-Aza-2-Deoxycytidine, a Potent Inhibitor of DNA Methylation, in Cancer Therapy <b>2005</b> , 205-217		1
77	Enhancement of antineoplastic action of 5-aza-2-Deoxycytidine by zebularine on L1210 leukemia. <i>Anti-Cancer Drugs</i> , <b>2005</b> , 16, 301-8	2.4	52
76	Enhancement of antineoplastic action of 5-aza-2-Deoxycytidine by phenylbutyrate on L1210 leukemic cells. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 147-54	1.9	17
75	Action of troxacitabine on cells transduced with human cytidine deaminase cDNA. <i>Cancer Investigation</i> , <b>2004</b> , 22, 25-9	2.1	3
74	Evaluation of antineoplastic action of 5-aza-2-Deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. <i>Anti-Cancer Drugs</i> , <b>2004</b> , 15, 161-7	2.4	33
73	Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2-Deoxycytidine (Decitabine). <i>Anticancer Research</i> , <b>2004</b> , 24, 75-8	2.3	20
72	Antineoplastic action of 5-aza-2-Deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells. <i>Oncology Reports</i> , <b>2004</b> , 11, 1253-6	3.5	17
71	Interaction of 5-aza-2-Deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. <i>Anti-Cancer Drugs</i> , <b>2003</b> , 14, 193-202	2.4	36
70	Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2-Deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. <i>International Journal of Cancer</i> , <b>2003</b> , 103, 177-84	7.5	77
69	Cancer epigenetics. <i>Oncogene</i> , <b>2003</b> , 22, 6479-83	9.2	236
68	Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2-Deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. <i>Leukemia Research</i> , <b>2003</b> , 27, 437-44	2.7	91
67	Antineoplastic action of 5-aza-2-Deoxycytidine and phenylbutyrate on human lung carcinoma cells. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13, 869-74	2.4	55

66	Cytotoxic activity of 2 $\beta$ -deoxy-2-fluorodeoxycytidine, 5-aza-2-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 293, 1478-84	3.4	23
65	Antineoplastic action of 5-aza-2-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 48, 71-6	3.5	104
64	Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene. <i>Cancer Gene Therapy</i> , <b>2001</b> , 8, 669-76	5.4	27
63	Potential of 5-aza-2-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2001</b> , 34 Suppl 4, S111-5	5.9	83
62	Evaluation of an inhibitor of DNA methylation, 5-aza-2-deoxycytidine, for the treatment of lung cancer and the future role of gene therapy. <i>Advances in Experimental Medicine and Biology</i> , <b>2000</b> , 465, 433-46	3.6	22
61	DNA methylation and cancer. <i>Journal of Cellular Physiology</i> , <b>2000</b> , 183, 145-54	7	315
60	Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2-deoxycytidine in tumor cells using a single-nucleotide primer extension assay. <i>Analytical Biochemistry</i> , <b>2000</b> , 281, 55-61	3.1	5
59	Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. <i>Cancer Gene Therapy</i> , <b>2000</b> , 7, 757-65	5.4	14
58	Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 278, 569-75	3.4	5
57	Gene amplification of human cytidine deaminase proviral cDNA and increased levels of its mRNA produces enhanced drug resistance to cytosine arabinoside in retroviral-transduced murine fibroblasts. <i>Cancer Letters</i> , <b>1999</b> , 135, 29-36	9.9	3
56	DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2-deoxycytidine. <i>Anti-Cancer Drugs</i> , <b>1999</b> , 10, 471-6	2.4	59
55	Effect of 5-aza-2-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 41, 275-80	3.5	12
54	Drug resistance to 5-aza-2-deoxycytidine, 2 $\beta$ -deoxy-2-fluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 373-8	3.5	87
53	Coexpression of Cytidine Deaminase and Mutant Dihydrofolate Reductase by a Bicistronic Retroviral Vector Confers Resistance to Cytosine Arabinoside and Methotrexate. <i>Human Gene Therapy</i> , <b>1998</b> , 9, 2537-2544	4.8	2
52	Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate. <i>Human Gene Therapy</i> , <b>1998</b> , 9, 2537-44	4.8	20
51	Demethylation by 5-aza-2-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. <i>Anti-Cancer Drugs</i> , <b>1998</b> , 9, 743-50	2.4	82
50	Pilot phase I-II study on 5-aza-2-deoxycytidine (Decitabine) in patients with metastatic lung cancer. <i>Anti-Cancer Drugs</i> , <b>1997</b> , 8, 358-68	2.4	173
49	Activation of the retinoic acid receptor beta gene by 5-aza-2-deoxycytidine in human DLD-1 colon carcinoma cells. <i>Anti-Cancer Drugs</i> , <b>1997</b> , 8, 56-61	2.4	49

48	Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. <i>Anti-Cancer Drugs</i> , <b>1996</b> , 7, 266-74	2.4	23
47	Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogs. <i>Leukemia Research</i> , <b>1996</b> , 20, 761-9	2.7	18
46	Comparison of the induction of apoptosis in human leukemic cell lines by 2 $\uparrow$ 2 $\uparrow$ Fdifluorodeoxycytidine (gemcitabine) and cytosine arabinoside. <i>Leukemia Research</i> , <b>1995</b> , 19, 849-56	2.7	42
45	Enhancement of the antileukemic activity of 5-aza-2 $\uparrow$ deoxycytidine by cyclopentenyl cytosine in HL-60 leukemic cells. <i>Anti-Cancer Drugs</i> , <b>1994</b> , 5, 223-8	2.4	13
44	Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2 $\uparrow$ deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. <i>Anti-Cancer Drugs</i> , <b>1993</b> , 4, 327-33	2.4	12
43	Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells. <i>Leukemia Research</i> , <b>1993</b> , 17, 749-57	2.7	29
42	Kinetic studies on 2 $\uparrow$ 2 $\uparrow$ Fdifluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. <i>Biochemical Pharmacology</i> , <b>1993</b> , 45, 1857-61	6	157
41	Effects of 5-aza-2 $\uparrow$ deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. <i>Anti-Cancer Drugs</i> , <b>1992</b> , 3, 281-7	2.4	3
40	Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2 $\uparrow$ deoxycytidine by human cytidine deaminase. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1992</b> , 30, 7-11	3.5	95
39	Comparison of antineoplastic activity of 2 $\uparrow$ 2 $\uparrow$ Fdifluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. <i>Anti-Cancer Drugs</i> , <b>1991</b> , 2, 49-55	2.4	30
38	Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine. <i>International Journal of Cancer</i> , <b>1991</b> , 49, 573-6	7.5	9
37	Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2 $\uparrow$ deoxycytidine. <i>Leukemia Research</i> , <b>1990</b> , 14, 751-4	2.7	27
36	Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2 $\uparrow$ deoxycytidine against human leukemic cells of different phenotype. <i>Leukemia Research</i> , <b>1990</b> , 14, 755-60	2.7	21
35	Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1990</b> , 27, 141-6	3.5	10
34	5-Aza-2 $\uparrow$ deoxycytidine as inducer of differentiation and growth inhibition in mouse neuroblastoma cells. <i>Cell Differentiation and Development</i> , <b>1989</b> , 27, 47-55		15
33	Preclinical evaluation of hematopoietic toxicity of antileukemic agent, 5-aza-2 $\uparrow$ deoxycytidine. <i>Toxicology</i> , <b>1989</b> , 57, 329-36	4.4	9
32	Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2 $\uparrow$ deoxycytidine and 3-deazauridine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1989</b> , 25, 51-4	3.5	22
31	Effects of 5-aza-2 $\uparrow$ deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. <i>Leukemia Research</i> , <b>1986</b> , 10, 533-7	2.7	13

30	Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2Fdeoxycytidine. <i>Leukemia Research</i> , <b>1985</b> , 9, 1361-6	2.7	66
29	Sample preparation for the determination of 5-aza-2Fdeoxycytidine in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , <b>1985</b> , 345, 162-7		10
28	Molecular, cellular and animal pharmacology of 5-aza-2Fdeoxycytidine <b>1985</b> , 30, 287-99		81
27	Clinical trial on 5-aza-2Fdeoxycytidine in patients with acute leukemia <b>1985</b> , 30, 277-86		129
26	Cell cycle effects and cellular pharmacology of 5-aza-2Fdeoxycytidine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1984</b> , 13, 191-4	3.5	43
25	Comparison of the antileukemic activity of 5-AZA-2Fdeoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. <i>Leukemia Research</i> , <b>1984</b> , 8, 1043-9	2.7	80
24	5-aza-2Fdeoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. <i>Leukemia Research</i> , <b>1984</b> , 8, 181-5	2.7	58
23	Kinetics of deamination of 5-aza-2Fdeoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. <i>Biochemical Pharmacology</i> , <b>1983</b> , 32, 1327-8	6	84
22	Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography. <i>Therapeutic Drug Monitoring</i> , <b>1983</b> , 5, 491-6	3.2	6
21	Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with 5-AZA-2Fdeoxycytidine and beta-2Fdeoxythioguanosine. <i>International Journal of Cancer</i> , <b>1982</b> , 30, 361-64	7.5	9
20	Biochemical pharmacology of cytosine arabinoside. <i>Medical and Pediatric Oncology</i> , <b>1982</b> , 10 Suppl 1, 45-8		22
19	Effects of trimethoprim on leukaemic cells in vitro. <i>British Journal of Haematology</i> , <b>1981</b> , 47, 221-6	4.5	5
18	Phase I study on 5-aza-2Fdeoxycytidine in children with acute leukemia. <i>Leukemia Research</i> , <b>1981</b> , 5, 453-62		166
17	In vitro systems for evaluation of combination chemotherapy <b>1980</b> , 8, 21-35		53
16	PHARMACOLOGY OF 5-AZA-2F-DEOXYCYTIDINE <b>1979</b> , 33-41		6
15	Kinetic studies with 5-azacytidine-5Ftriphosphate and DNA-dependent RNA polymerase. <i>Biochemical Pharmacology</i> , <b>1977</b> , 26, 403-6	6	7
14	Integration of biochemical, cellular, and animal pharmacology of antineoplastic agents to design new model drug combinations for treatment of acute leukemia. <i>Leukemia Research</i> , <b>1977</b> , 1, 315-322	2.7	1
13	Relationship of nutritional factors to in vitro tumor cell growth and cytotoxicity produced by cytosine arabinoside. <i>Cell Proliferation</i> , <b>1977</b> , 10, 127-35	7.9	

12	Effect of tRNA from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system. <i>Biochemical Pharmacology</i> , <b>1976</b> , 25, 389-92	6	19
11	Inhibition of uridine-cytidine kinase by 5-azacytidine 5'Triphosphate. <i>Medical and Pediatric Oncology</i> , <b>1976</b> , 2, 265-70		4
10	Enzymatic synthesis of 5-azacytidine 5'Triphosphate from 5-azacytidine. <i>Analytical Biochemistry</i> , <b>1976</b> , 71, 60-7	3.1	10
9	Effect of DNA polymerase on nuclei from different phases of cell cycle. <i>FEBS Journal</i> , <b>1974</b> , 49, 565-71		8
8	Partial Purification and Properties of Two Forms of Deoxyribonucleic Acid Polymerase from Calf Thymus. <i>Journal of Biological Chemistry</i> , <b>1973</b> , 248, 285-293	5.4	44
7	Mammalian Deoxynucleoside Kinases. <i>Journal of Biological Chemistry</i> , <b>1971</b> , 246, 6152-6158	5.4	25
6	Mammalian Deoxynucleoside Kinases. <i>Journal of Biological Chemistry</i> , <b>1971</b> , 246, 2745-2751	5.4	34
5	Mammalian Deoxynucleoside Kinases. <i>Journal of Biological Chemistry</i> , <b>1971</b> , 246, 2752-2757	5.4	19
4	Studies on analogs of isosteric and allosteric ligands of deoxycytidylate aminohydrolase. <i>Biochemistry</i> , <b>1970</b> , 9, 2539-43	3.2	10
3	Effect of cytosine arabinoside 5'Triphosphate on mammalian DNA polymerase. <i>Biochemical and Biophysical Research Communications</i> , <b>1969</b> , 34, 464-71	3.4	98
2	Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. <i>Nucleic Acids and Protein Synthesis</i> , <b>1968</b> , 161, 481-93		59
1	The regulatory properties of deoxyadenosine kinase. <i>Nucleic Acids and Protein Synthesis</i> , <b>1968</b> , 161, 578-80		9